Barclays analyst Matt Miksic initiated coverage of Alcon (ALC) with an Equal Weight rating and $86 price target Alcon is the market leader in intraocular lenses and a share-gainer in contact lenses, the analyst tells investors in a research note. However, the firm says a slowdown in the cataract market and slower than expected equipment replacement cycle represent near-term challenges to the company’s growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Broadwood issues letter to Staar Surgical board questioning ‘rush’ in Alcon sale
- Staar Surgical board reiterates support of Alcon merger agreement
- Broadwood: Glass Lewis uring Staar Surgical investors to vote against Alcon deal
- Defender Capital says opposes Staar Surgical’s proposed sale to Alcon
- Yunqi Capital urges STAAR shareholders to oppose Alcon merger